CONNECT BIOPHARMA HOLDINGS L (CNTB) Stock Price & Overview
NASDAQ:CNTB • KYG235491019
Current stock price
The current stock price of CNTB is 2.49 USD. Today CNTB is down by -1.19%. In the past month the price decreased by -31.71%. In the past year, price increased by 222.66%.
CNTB Key Statistics
- Market Cap
- 138.747M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.64
- Dividend Yield
- N/A
CNTB Stock Performance
CNTB Stock Chart
CNTB Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CNTB. When comparing the yearly performance of all stocks, CNTB is one of the better performing stocks in the market, outperforming 96.38% of all stocks.
CNTB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNTB. CNTB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CNTB Earnings
CNTB Forecast & Estimates
11 analysts have analysed CNTB and the average price target is 8.54 USD. This implies a price increase of 243.07% is expected in the next year compared to the current price of 2.49.
For the next year, analysts expect an EPS growth of -58.23% and a revenue growth -100% for CNTB
CNTB Groups
Sector & Classification
CNTB Financial Highlights
Over the last trailing twelve months CNTB reported a non-GAAP Earnings per Share(EPS) of -2.64. The EPS decreased by -252.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -98.94% | ||
| ROE | -132.16% | ||
| Debt/Equity | 0 |
CNTB Ownership
CNTB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.47 | 351.47B | ||
| AMGN | AMGEN INC | 15.04 | 185.95B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 161.855B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.07 | 109.449B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 79.456B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.29 | 40.768B | ||
| INSM | INSMED INC | N/A | 29.176B | ||
| NTRA | NATERA INC | N/A | 28.878B | ||
| BIIB | BIOGEN INC | 11.36 | 27.06B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.812B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.56 | 24.859B | ||
| MRNA | MODERNA INC | N/A | 20.119B | ||
| INCY | INCYTE CORP | 12.41 | 18.836B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CNTB
Company Profile
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 62 full-time employees. The company went IPO on 2021-03-19. The firm is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The firm has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Company Info
IPO: 2021-03-19
CONNECT BIOPHARMA HOLDINGS L
3580 Carmel Mountain Road, Suite 200
San Diego CALIFORNIA 215400 US
CEO: William Pan
Employees: 62
Phone: 18587271040
CONNECT BIOPHARMA HOLDINGS L / CNTB FAQ
Can you describe the business of CONNECT BIOPHARMA HOLDINGS L?
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 62 full-time employees. The company went IPO on 2021-03-19. The firm is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The firm has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
What is the current price of CNTB stock?
The current stock price of CNTB is 2.49 USD. The price decreased by -1.19% in the last trading session.
Does CONNECT BIOPHARMA HOLDINGS L pay dividends?
CNTB does not pay a dividend.
What is the ChartMill rating of CONNECT BIOPHARMA HOLDINGS L stock?
CNTB has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of CONNECT BIOPHARMA HOLDINGS L (CNTB)?
CONNECT BIOPHARMA HOLDINGS L (CNTB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.64).
What is the market capitalization of CNTB stock?
CONNECT BIOPHARMA HOLDINGS L (CNTB) has a market capitalization of 138.75M USD. This makes CNTB a Micro Cap stock.